Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00945789

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial

Sponsor: Tanta University

Conditions Hypoxic Ischemic Encephalopathy

Interventions EEG and Brain MRI Human recombinant erythropoietin Nitric oxide measurement in the blood

Updated 5 times since 2017 Last updated: Sep 24, 2009 Started: Oct 31, 2007 Primary completion: Dec 31, 2008 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Hypoxic Ischemic Encephalopathy and is currently completed. Tanta University leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanta University

Data source: Tanta University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tanta, Egypt